We are excited to announce our participation in the upcoming EASD Congress in Madrid from 9th-13th September. At this prestigious event, we will present our latest research on GABAA receptor activation, introducing it as a novel first-in-class approach for the treatment of MASH. This innovative therapy represents a significant advancement in addressing the unmet needs in metabolic disease management. We look forward to sharing our findings, learn more about the comorbitdity diabetes and engaging with the global scientific community.